• Platform & Pipeline
    • Opportunity
    • CAR T-Cell Therapy
    • Pipeline
    • Clinical Trials and Expanded Access
  • Patients
    • Experience
    • Stiff Person Syndrome
    • Myasthenia Gravis
    • Multiple Sclerosis
  • Inside Kyverna
    • Leadership
    • Mission & Values
  • Knowledge Center
    • Publications
    • Videos
  • Investors
  • News
  • Careers
  • Contact

Pipeline

A focused pipeline of B-cell targeting therapies to address autoimmune diseases.

Pipeline chart

Learn more about our disease targets

Stiff Person Syndrome
Myasthenia Gravis
Multiple Sclerosis

Links

  • Home
  • Platform & Pipeline
  • Patients
  • Inside Kyverna
  • Knowledge Center
  • Investors
  • Careers
  • Contact

About

Kyverna is a late-stage clinical immunology company pioneering differentiated therapies with curative potential for neurologic autoimmune diseases.

Our lead autologous CD19-targeting CAR T-cell therapy candidate, miv-cel (mivocabtagene autoleucel, KYV-101), has demonstrated the potential to fundamentally change the treatment paradigm across multiple B-cell-driven autoimmune diseases. Kyverna is advancing its potentially first-in-class neuroimmunology franchise with its recently completed registrational trial in stiff person syndrome and an ongoing registrational trial for generalized myasthenia gravis.

Kyverna is also harnessing other KYSA trials and investigator-initiated trials, as well as next generation innovations to expand patient access and evaluate future indications.

FOLLOW US ON SOCIAL

  • Privacy Policy (US)
  • Privacy Policy (EU/UK)

Designed by Elegant Themes | Powered by WordPress